Canadian AIDS Treatment Information Exchange
click here to return to CATIE main menu
DonateNow

Toxicity profile of HAART

TreatmentUpdate 123 - 2001 November/December; Volume 13 Issue 7
Hosein SR
click here for french langage version of article

Because there is no combination of anti-HIV drugs that is best for everyone, therapy has to be tailored to the needs of each person. Decisions about choosing therapies are usually based on individual factors such as CD4+ cell count, viral load and the presence of symptoms of HIV/AIDS. Other factors, such as the ability to meet food, water and strict schedule requirements of certain regimens and the ability to endure certain side effects, likely play a role as well. Another point to bear in mind is that in the real world reports of side effects are usually greater than those that are received during clinical trials.

Doctors in Madrid, Spain, reviewed data on 499 subjects with HIV/AIDS who started taking HAART between the years 1996 and 2000. Their aim was to find out about drug-related side effects. These doctors collected data from PHAs attending an HIV/AIDS clinic.

Results

Overall, about 34% of subjects (172 subjects) developed drug-related side effects. In most of these cases (145 of 172 subjects, or 84%), subjects had to stop using the drug that caused the side effect. The following is a list of drugs and the proportion of users who experienced side effects as well as the most common side effects:

The drugs that caused the most side effects were as follows:

The researchers found that, on average, subjects had taken HAART for about a year before signs/symptoms of lipodystrophy appeared.

REFERENCE

1. Moreno A, Perez-Elías MJ, Casado JL, et al. Toxicity profile of antiretroviral drugs in naïve patients starting highly active antiretroviral therapy in routine clinical practice. Abstract 93 - 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 23-26 October 2001, Athens, Greece.

20011210
CATE12303


Copyright © 2001 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284  http://www.catie.ca.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.